Health and fertility in World Health Organization group 2 anovulatory women
Authors:
- ESHRE Capri Workshop GroupEGESHRE Capri Workshop Group
- D. T. BairdDBD. T. Baird
- A. BalenABA. Balen
- H. F. Escobar-MorrealeHEH. F. Escobar-Morreale
- J. L. H. EversJEJ. L. H. Evers
- B. C. J. M. FauserBFB. C. J. M. Fauser
- S. FranksSFS. Franks
- A. GlasierAGA. Glasier
- R. HomburgRHR. Homburg
- C. La VecchiaCVC. La Vecchia
- P. DevroeyPDP. Devroey
- K. DiedrichKDK. Diedrich
Open Access
- 19 May 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 18 (5) , 586-599
Abstract
Disruption of ovulation occurs in different types of clinical infertility. The World Health Organization (WHO) has provided a classification of ovulation disorders. This review focuses on WHO group 2 anovulation. Searches were performed in Medline/PubMed and EMBASE. Each subject summary was presented to the European Society of Human Reproduction and Embryology (ESHRE) Workshop Group, where omissions or disagreements were resolved by discussion. Disorders resulting in ovulatory disturbances are a relatively common cause of infertility. They occur most frequently in the context of WHO group 2 anovulation as reflected, for example, in the polycystic ovary syndrome (PCOS). The aetiology of PCOS remains unclear but evidence exists for a multifactorial origin with a genetic predisposition. Women with PCOS show an increased time to pregnancy but their eventual family size is not necessarily reduced. Also their frequency of miscarriage does not appear increased. Clomiphene citrate is still the first-line treatment in subfertile anovulatory patients with PCOS, with gonadotrophins and laparoscopic ovarian surgery as second-line options. Aromatase inhibitors show promising results. Long-term health risks in patients with WHO group 2 anovulation demand their general health be monitored, even after their reproductive needs have been fulfilled. Metabolic and cardiovascular risk prevention in women with PCOS should start as early as possible. It is not easy to analyse the possible role of PCOS, independent of obesity, metabolic syndrome, insulin resistance and diabetes, on long-term health.Keywords
This publication has 110 references indexed in Scilit:
- Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome SocietyHuman Reproduction Update, 2011
- Genetics and epigenetics of obesityMaturitas, 2011
- Cholesterol, endocrine and metabolic disturbances in sporadic anovulatory women with regular menstruationHuman Reproduction, 2010
- Primary ovarian insufficiencyThe Lancet, 2010
- Prestimulation parameters predicting live birth in anovulatory WHO Group II patients undergoing ovulation induction with gonadotrophinsHuman Reproduction, 2010
- Type 2 diabetes, cardiovascular disease, and the evolutionary paradox of the polycystic ovary syndrome: A fertility first hypothesisAmerican Journal of Human Biology, 2009
- Epigenetic abnormality: A possible mechanism underlying the fetal origin of polycystic ovary syndromeMedical Hypotheses, 2008
- Polycystic Ovary Syndrome and Oocyte Developmental CompetenceObstetrical & Gynecological Survey, 2008
- Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studiesAmerican Journal of Obstetrics and Gynecology, 2007
- Potential association between infertility and spinal neural tube defects in offspringBirth Defects Research Part A: Clinical and Molecular Teratology, 2006